

Utilization Management and Clinical Medical Policy

Policy Name: Krystexxa® (pegloticase)	Policy Number: MP-RX-FP-50-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	---	---	--	---

Service Category:

- | | |
|--|---|
| ☐ Anesthesia | ☐ Medicine Services and Procedures |
| ☐ Surgery | ☐ Evaluation and Management Services |
| ☐ Radiology Procedures | ☐ DME/Prosthetics or Supplies |
| ☐ Pathology and Laboratory Procedures | ☒ Other: Part B Drugs |

Service Description:

This document addresses the use of *Krystexxa (pegloticase)*. Krystexxa is a recombinant uricase enzyme that achieves its therapeutic effect by catalyzing the oxidation of uric acid to allantoin, thereby lowering serum uric acid. Krystexxa is approved by the Food and Drug Administration for the treatment of chronic gout in adults that are refractory to conventional therapy.

Background Information:

In the clinical trials that supported the approval of Krystexxa, chronic refractory gout was defined as three or more self-reported gout flares during the previous 18 months, one or more tophi or gouty arthropathy defined clinically or radiographically as joint damage due to gout. Krystexxa should be co-administered with weekly methotrexate and folic acid/folinic acid supplementation unless contraindicated or not clinically appropriate. Methotrexate co-administration decreases anti-drug antibody incidence rate and titers, therefore allowing for increased Krystexxa exposure levels.

The 2020 American College of Rheumatology (ACR) guidelines for the management of gout strongly recommend allopurinol as the preferred first-line agent for individuals starting urate-lowering therapy (ULT), including those with chronic kidney disease (CKD) stage >3. The guidelines also strongly recommend a xanthine oxidase inhibitor over probenecid for those with CKD stage >3. For individuals on ULT, the ACR recommends targeting a serum urate level <6 mg/dL. The guidelines strongly recommend switching to Krystexxa in individuals for whom xanthine oxidase inhibitors, uricosurics and other interventions have failed to achieve the serum urate target and who continue to have frequent gout flares (≥2 flares/year) or who have nonresolving subcutaneous tophi.

Krystexxa has a black box warning for anaphylaxis and infusion reactions, and glucose-6-phosphate dehydrogenase (G6PD) deficiency associated hemolysis and methemoglobinemia. Krystexxa should be administered in a healthcare setting and by healthcare providers prepared to manage anaphylaxis and infusion reactions. Individuals should be pre-medicated with antihistamines and corticosteroids for each infusion and closely monitored for symptoms of anaphylaxis. Monitor serum uric acid levels prior to infusions and consider discontinuing treatment if levels increase to above 6 mg/dL, particularly when two consecutive levels above 6 mg/dL are observed. Individuals at risk for G6PD deficiency (including African, Mediterranean and Southern Asian ancestry) should be screened prior to starting Krystexxa. Hemolysis and methemoglobinemia have been reported with Krystexxa in individuals with G6PD deficiency. Do not administer Krystexxa to individuals with G6PD deficiency.

Medical Policy

Utilization Management and Clinical Medical Policy

Policy Name: Krystexxa® (pegloticase)	Policy Number: MP-RX-FP-50-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	---	---	--	---

Approved Indications

- A. Treatment of chronic gout in adults refractory to conventional therapy

Other Uses

- A. None.

Utilization Management and Clinical Medical Policy

Policy Name: Krystexxa® (pegloticase)	Policy Number: MP-RX-FP-50-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	---	---	--	---

Medical Necessity Guidelines:

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

Pegloticase (Krystexxa®)

A. Criteria For Initial Approval

- i. Individual is 18 years of age or older; **AND**
- ii. Individual has a diagnosis of chronic gout demonstrated by one or more of the following (Sundy 2011):
 - A. Three or more gout flares in the previous 18 months; **OR**
 - B. One or more tophus present; **OR**
 - C. History of chronic gouty arthropathy, defined clinically or radiographically as joint damage due to gout.

AND

- iii. Documentation is provided that individual has a baseline serum uric acid of 6 mg/dL or greater prior to initiating Krystexxa (pegloticase) (FitzGerald 2020); **AND**
- iv. Documentation is provided that individual has failed to respond to, is intolerant of, or has a medical contraindication to 1 or more of the following conventional therapies (FitzGerald 2020):
 - A. A xanthine oxidase inhibitor (allopurinol or febuxostat); **OR**
 - B. Combination therapy of 1 xanthine oxidase inhibitor given with a uricosuric agent (for example, probenecid); **AND**
- v. Krystexxa (pegloticase) will be administered in combination with methotrexate and folic acid/folinic acid supplementation unless contraindicated or not clinically appropriate.

B. Criteria For Continuation of Therapy

Continuation requests for Krystexxa (pegloticase) may be approved if the following criterion is met:

- i. There is clinically significant improvement in clinical signs and symptoms of disease (including but not limited to reduction in serum uric acid level, gout flare reduction, tophus resolution, reduction in joint pain) (Sundy 2011); **AND**
- ii. Krystexxa (pegloticase) will be administered in combination with methotrexate and folic acid/folinic acid supplementation unless contraindicated or not clinically appropriate.

C. Authorization Duration

- i. Initial Approval Duration: 1 year
- ii. Reauthorization Approval Duration: 1 year

D. Conditions Not Covered

Any other use is considered experimental, investigational, or unproven, including the following (this list may not be all inclusive):

Utilization Management and Clinical Medical Policy

Policy Name: Krystexxa® (pegloticase)	Policy Number: MP-RX-FP-50-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	--	--	--	---

- i. Individual has asymptomatic hyperuricemia; **OR**
- ii. Individual has a known glucose-6-phosphate dehydrogenase (G6PD) deficiency; **OR**
- iii. Individual is using in combination with oral urate-lowering therapy (including but not limited to allopurinol, febuxostat, probenecid); **OR**
- iv. For continuation requests, the two most recent serum uric acid levels have been 6 mg/dL or greater; **OR**
- v. May not be approved when the above criteria (Section A) are not met and for all other indications.

Utilization Management and Clinical Medical Policy

Policy Name: Krystexxa® (pegloticase)	Policy Number: MP-RX-FP-50-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	---	---	--	---

Limits or Restrictions:

A. Therapeutic Alternatives

The list below includes preferred alternative therapies recommended in the approval criteria and may be subject to prior authorization.

- i. N/A

B. Quantity Limitations

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines. The chart below includes dosing recommendations as per the FDA-approved prescribing information.

Drug	Recommended Dosage	Limit
Krystexxa (pegloticase) inj. 8 mg/mL single dose vial	8 mg IV every two weeks co-administered with weekly methotrexate 15 mg orally.	2 vials per 28 days

Utilization Management and Clinical Medical Policy

Policy Name: Krystexxa® (pegloticase)	Policy Number: MP-RX-FP-50-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	--	--	--	---

Codes Information:

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

ICD-10 Diagnostic Codes:

Codes	Description
M1A.00X0-M1A.9XX1	Chronic gout
M10.00-M10.9	Gout

HCPCS Codes:

Codes	Description
J2507	Injection, pegloticase, 1mg [Krystexxa]

Reference Information:

1. Amgen Inc. (2025, August). KRYSTEXXA® (pegloticase) injection, for intravenous use: Full prescribing information. Accessed June 8, 2026.
2. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. *Arthritis Rheumatol.* 2020;72(6):879-895. Available at: <https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.41247>.
3. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care Res.* 2012; 64: 1431-46.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc. Updated periodically.
5. Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. *JAMA.* 2011; 306:711–720.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

Medical Policy

Utilization Management and Clinical Medical Policy

Policy Name: Krystexxa® (pegloticase)	Policy Number: MP-RX-FP-50-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	---	---	--	---

Policy History:

Type of Review	Summary of Changes	P&T Approval Date	UM/CMPC Approval Date
Annual Review	Removed gouty arthritis and symptomatic hyperuricemia from FDA approved indications. Coding Reviewed: No changes. Added recommended dosage and updated reference information. Administrative update to incorporate new policy template.	8/14/2026	8/19/2026
Annual Review	Minimal changes; Word formatting. Coding reviewed: No changes.	9/5/2025	9/16/2025
Annual Review	Annual Review: Add quantity limit.	11/18/2024	12/17/2024
Policy Inception	Elevance Health's Medical Policy adopted.	N/A	11/30/2023